Contributions
Abstract: P1220
Type: Poster
Abstract Category: Therapy - disease modifying - Long-term treatment monitoring
Objective: to evaluate whether lymphocytes sub-population could be related to MS disease reactivation at natalizumab suspension.
Background. Natalizumab is a very effective second-line treatment for active MS but its suspension can cause MS disease reactivation and rebound. At the moment the only risk factor for disease reactivation is the number of relapses before natalizumab introduction. Previously it has been suggested that low blood lymphocytes count during natalizumab treatment could be a risk factor for MS reactivation.
Methods: Data were retrospectively collected from one Italian MS centre. Peripheral lymphocyte subsets were analyzed by FACS in 91 MS patients before natalizumab discontinuation.
Results. At the end of natalizumab treatment, a high percentage of CD4+ (OR 0.61) and a high CD4+/CD8+ ratio (OR 0.56) confer a low risk of disease reactivation. On the contrary, a high percentage of CD8+ cells is a risk factor for disease reactivation (OR 1.22). No correlation has been found for CD19+ and CD16+56+ cells. Roc analysis show a significant threshold for CD4+ cells of 40.45 with an OR of 2.65 (p-value 0.034).
Conclusion. Lymphocytes sub-population analysis could add important information on the risk of disease reactivation after natalizumab; in particular a low percentage of CD4 cells can predict disease reactivation.
Disclosure:
Lo Re M received travel expenses from Biogen, Novartis and Teva. Capobianco M received speaking honoraria and/or consultant fees from Biogen, Merck-Serono, Novartis, Teva, Genzyme and Almirall. Malucchi S received speaking honoraria from Biogen, Novartis, Teva. Malentacchi M received speaking honoraria from Biogen. di Sapio A received consultant fees from Biogen, Merck Serono. Matta M, received speaking honoraria from Biogen, Almirall. Sperli F received speaking honoraria from Biogen. Oggero A, received speaking honoraria from Biogen. Berchialla P has nothing to disclosure. Pautasso M has nothing to disclosure. Bertolotto A. received honoraria for serving in the scientific advisory boards of Almirall, Bayer, Biogen, Genzyme with approval by the Director of AOU San Luigi University Hospital and received speaker honoraria from Biogen, Genzyme, Novartis, TEVA; his institution has received grant support from Bayer, Biogen, Merck, Novartis, TEVA from the Italian Multiple Sclerosis Society, Fondazione Ricerca Biomedica ONLUS and San Luigi ONLUS
Abstract: P1220
Type: Poster
Abstract Category: Therapy - disease modifying - Long-term treatment monitoring
Objective: to evaluate whether lymphocytes sub-population could be related to MS disease reactivation at natalizumab suspension.
Background. Natalizumab is a very effective second-line treatment for active MS but its suspension can cause MS disease reactivation and rebound. At the moment the only risk factor for disease reactivation is the number of relapses before natalizumab introduction. Previously it has been suggested that low blood lymphocytes count during natalizumab treatment could be a risk factor for MS reactivation.
Methods: Data were retrospectively collected from one Italian MS centre. Peripheral lymphocyte subsets were analyzed by FACS in 91 MS patients before natalizumab discontinuation.
Results. At the end of natalizumab treatment, a high percentage of CD4+ (OR 0.61) and a high CD4+/CD8+ ratio (OR 0.56) confer a low risk of disease reactivation. On the contrary, a high percentage of CD8+ cells is a risk factor for disease reactivation (OR 1.22). No correlation has been found for CD19+ and CD16+56+ cells. Roc analysis show a significant threshold for CD4+ cells of 40.45 with an OR of 2.65 (p-value 0.034).
Conclusion. Lymphocytes sub-population analysis could add important information on the risk of disease reactivation after natalizumab; in particular a low percentage of CD4 cells can predict disease reactivation.
Disclosure:
Lo Re M received travel expenses from Biogen, Novartis and Teva. Capobianco M received speaking honoraria and/or consultant fees from Biogen, Merck-Serono, Novartis, Teva, Genzyme and Almirall. Malucchi S received speaking honoraria from Biogen, Novartis, Teva. Malentacchi M received speaking honoraria from Biogen. di Sapio A received consultant fees from Biogen, Merck Serono. Matta M, received speaking honoraria from Biogen, Almirall. Sperli F received speaking honoraria from Biogen. Oggero A, received speaking honoraria from Biogen. Berchialla P has nothing to disclosure. Pautasso M has nothing to disclosure. Bertolotto A. received honoraria for serving in the scientific advisory boards of Almirall, Bayer, Biogen, Genzyme with approval by the Director of AOU San Luigi University Hospital and received speaker honoraria from Biogen, Genzyme, Novartis, TEVA; his institution has received grant support from Bayer, Biogen, Merck, Novartis, TEVA from the Italian Multiple Sclerosis Society, Fondazione Ricerca Biomedica ONLUS and San Luigi ONLUS